BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/20/2015 1:37:00 PM | Browse: 592 | Download: 593
Publication Name World Journal of Gastroenterology
Manuscript ID 16923
Country/Territory Germany
2015-02-03 08:47
Peer-Review Started
2015-02-05 19:06
To Make the First Decision
2015-04-24 19:18
Return for Revision
2015-04-26 16:02
2015-05-12 01:25
Second Decision
2015-07-17 16:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2015-07-18 11:09
Articles in Press
2015-07-18 11:09
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-08-05 15:53
Publish the Manuscript Online
2015-08-20 13:37
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Review
Article Title Perspectives in the treatment of pancreatic adenocarcinoma
Manuscript Source Invited Manuscript
All Author List Angel Cid-Arregui and Victoria Juarez
Funding Agency and Grant Number
Corresponding author Angel Cid-Arregui, MD, PhD, German Cancer Research Center, Translational Immunology, Tumor Immunology Program, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. a.cid@dkfz.de
Key Words Pancreatic adenocarcinoma; Tumor surveillance; Biomarkers; Immune surveillance; Chemotherapy; Immunotherapy; Antibody therapy; Adoptive T cell therapy; Vaccines; Stroma; Inhibitors
Core Tip Pancreatic adenocarcinoma is a life threatening, fast evolving disease for which there is no cure. Recently, new chemotherapy regimens have shown significant improvement in survival in patients with advanced disease, opening a way for further progress. New therapeutic strategies based on targeted inhibitors or immunotherapy approaches, in particular antibody and adoptive T cell therapies, are getting growing attention as they are proving beneficial in pre-clinical and early phase clinical studies in combination with chemotherapy. Progress in understanding pancreatic tumor genetics, epigenetics and metabolism is providing new biomarkers that may be of value in early detection and progression assessments.
Publish Date 2015-08-20 13:37
Citation Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 2015; 21(31): 9297-9316
Url http://www.wjgnet.com/1007-9327/full/v21/i31/9297.htm
DOI http://dx.doi.org/10.3748/wjg.v21.i31.9297
Full Article (PDF) WJG-21-9297.pdf
Full Article (Word) WJG-21-9297.doc
Manuscript File 16923-Review.docx
Answering Reviewers 16923-Answering reviewers.pdf
Audio Core Tip 16923-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 16923-Conflict-of-interest statement.pdf
Copyright License Agreement 16923-Copyright assignment.pdf
Peer-review Report 16923-Peer-review(s).pdf
Scientific Misconduct Check 16923-Scientific misconduct check.pdf
Scientific Editor Work List 16923-Scientific editor work list.pdf